Stephanie Burns - GSK Plc Non-Executive Independent Director
| GLAXF Stock | USD 19.85 0.31 1.59% |
Director
Dr. Stephanie Ann Burns Ph.D. is no longer NonExecutive Independent Director of GlaxoSmithKline PLC effective 5 May 2016. Stephanie is a recognised global business leader having served as Chairman President and CEO of Dow Corning Corporation until her retirement at the end of 2011. She has a strong scientific background with a PhD in organic chemistry with an organosilicon specialty and is an advocate for science education. Stephanie previously sat on the US Presidents Export Council and was an Officer of the Society of Chemical Industry American Section as well as the past Honorary President of the UKbased parent society. Stephanie was also an Officer and Chairman of the American Chemistry Council. External appointments Stephanie was appointed a NonExecutive Director of Corning Inc. in January 2012 and a NonExecutive Director of Kellogg Company in February 2014. since 2007.
| Age | 60 |
| Tenure | 17 years |
| Professional Marks | Ph.D |
| Phone | 44 20 8047 5000 |
| Web | https://www.gsk.com |
GSK Plc Management Efficiency
The company has return on total asset (ROA) of 0.0659 % which means that it generated a profit of $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3131 %, meaning that it generated $0.3131 on every $100 dollars invested by stockholders. GSK Plc's management efficiency ratios could be used to measure how well GSK Plc manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Satoshi Suzuki | Santen Pharmaceutical Co | N/A | |
| Yutaro Shintaku | Santen Pharmaceutical Co | 62 | |
| Uwe Bicker | Sanofi ADR | 69 | |
| Takayuki Katayama | Santen Pharmaceutical Co | 72 | |
| Weiying Wang | AstraZeneca PLC ADR | N/A | |
| Carina Lazaro | Grifols SA ADR | 48 | |
| Andreas Planta | Novartis AG ADR | 65 | |
| DeAnne Julius | Roche Holding Ltd | 66 | |
| Susan Hockfield | Pfizer Inc | 70 | |
| Helen Hobbs | Pfizer Inc | 68 | |
| Marvinder Banga | GlaxoSmithKline PLC ADR | 66 | |
| Simon Dingemans | GlaxoSmithKline PLC ADR | 53 | |
| Diane Souza | Sanofi ADR | 65 | |
| Brett Ingersoll | Grifols SA ADR | N/A | |
| Akihiro Tsujimura | Santen Pharmaceutical Co | 50 | |
| Deborah DiSanzo | AstraZeneca PLC ADR | 59 | |
| Thomas Suedhof | Sanofi ADR | 62 | |
| Akihiro Okumura | Santen Pharmaceutical Co | 70 | |
| Tony Mok | AstraZeneca PLC ADR | N/A | |
| Marla Salmon | Grifols SA ADR | N/A | |
| Ann Cairns | AstraZeneca PLC ADR | 57 | |
Management Performance
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 |
GSK plc Leadership Team
Elected by the shareholders, the GSK Plc's board of directors comprises two types of representatives: GSK Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GSK. The board's role is to monitor GSK Plc's management team and ensure that shareholders' interests are well served. GSK Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GSK Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vindi Banga, Senior Independent Non-Executive Director | ||
| Lynn Elsenhans, Independent Non-Executive Director | ||
| Luke Miels, President - Global Pharmaceuticals | ||
| Hal Barron, Chief Scientific Officer and Presidentident - R&D, Executive Director | ||
| Daniel Podolsky, Non-Executive Independent Director | ||
| Emma Walmsley, President - Consumer Healthcare Worldwide | ||
| Luc Debruyne, President - Global Vaccines | ||
| Andrew Witty, CEO, Executive Director | ||
| Brian McNamara, CEO - GSK Consumer Healthcare | ||
| Roy Anderson, Non-Executive Independent Director | ||
| Philip Hampton, Independent Non-Executive Director | ||
| Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee | ||
| Vivienne Cox, Non-Executive Director | ||
| Bill Louv, Senior Vice President - Core Business Services | ||
| Diana Conrad, Chief Officer | ||
| Roger Connor, President - Global Manufacturing & Supply | ||
| Abbas Hussain, President Global Pharmaceuticals | ||
| Phil Thomson, Senior Vice President - Global Communications | ||
| Judy Lewent, Non-Executive Independent Director | ||
| Hans Wijers, Independent Non-Executive Director | ||
| Shobie Ramakrishnan, Chief Officer | ||
| Sarah EltonFarr, Head Relations | ||
| Stephanie Burns, Non-Executive Independent Director | ||
| Julie Brown, Chief Officer | ||
| Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee | ||
| Urs Rohner, Non-Executive Independent Director | ||
| Marvinder Banga, Senior Non-Executive Independent Director | ||
| Deryck Maughan, Senior Independent Non-Executive Director | ||
| Jesse Goodman, Non-Executive Director | ||
| Laurie Glimcher, Non-Executive Director | ||
| Nick Hirons, Senior Vice President - Global Ethics and Compliance | ||
| Sally Jackson, VP Office | ||
| James Ford, Senior Vice President General Counsel | ||
| Victoria Whyte, Company Secretary | ||
| Daniel Troy, Sr. VP and General Counsel | ||
| Shah Hussain, President - Europe, Japan & EMAP | ||
| Tony Wood, Chief Officer | ||
| Manvinder Banga, Non-Executive Director | ||
| David Redfern, Chief Strategy Officer | ||
| Patrick Vallance, President - Pharmaceuticals R&D | ||
| Stacey Cartwright, Non-Executive Independent Director | ||
| Regis Simard, President - Pharmaceutical Supply Chain | ||
| Iain Mackay, CFO - Designate, Executive Director | ||
| Karenann Terrell, Chief Digital & Technology Officer | ||
| Claire Thomas, Senior Vice President - Human Resources |
GSK Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is GSK Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 90.86 B | |||
| Shares Outstanding | 4.09 B | |||
| Shares Owned By Insiders | 0.60 % | |||
| Shares Owned By Institutions | 41.06 % | |||
| Price To Earning | 11.44 X | |||
| Price To Book | 6.49 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GSK Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GSK Plc's short interest history, or implied volatility extrapolated from GSK Plc options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GSK plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for GSK Pink Sheet analysis
When running GSK Plc's price analysis, check to measure GSK Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GSK Plc is operating at the current time. Most of GSK Plc's value examination focuses on studying past and present price action to predict the probability of GSK Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GSK Plc's price. Additionally, you may evaluate how the addition of GSK Plc to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |